A Nomogram to Predict the Overall Survival of Patients With Resected T1-2N0-1M0 Non-Small Cell Lung Cancer and to Identify the Optimal Candidates for Adjuvant Chemotherapy in Stage IB or IIA Non-Small Cell Lung Cancer Patients

Overview

Journal Cancer Control

Specialty Oncology

Date 2023 Sep 13

PMID 37703536

Authors

Wei Wang

Juying Zhou

Affiliations

Soon will be listed here.

Abstract

Background: The benefit of adjuvant chemotherapy for IB/IIA non-small cell lung cancer (NSCLC) patients remains uncertain. This study aimed to develop a prognostic model to predict overall survival in resected NSCLC patients with T1-2N0-1M0 stage and identify optimal candidates for postoperative chemotherapy among those with stage IB or IIA disease.

Methods: We conducted a retrospective study using the SEER 18 database (2000-2018, November 2020 submission) of patients who underwent radical surgery for T1-2N0-1M0 NSCLC. The patients not receiving adjuvant chemotherapy were randomly divided into training and validation cohorts. A prognostic nomogram was established and evaluated using calibration and receiver operating characteristic curves. Based on the nomogram, stage IB and IIA patients were categorized into two prognostic groups, each further divided into cohorts based on adjuvant chemotherapy status. Kaplan-Meier analysis and log-rank tests were used to compare overall survival between these groups.

Results: A total of 14 789 patients were enrolled and randomly assigned to the training cohort (n = 10 352) and validation cohort (n = 4437). Ten independent prognostic factors were identified and integrated into the prognostic model. The area under the receiver operating characteristic curve was .706, .699, and .705 in the training cohort, and .700, .698, and .695 in the validation cohort at 1, 3, and 5 years, respectively. Among stage IB and IIA patients, only those in the high-risk group showed a significant benefit from adjuvant chemotherapy, with a 16.4% absolute increase in 5-year overall survival.

Conclusions: The nomogram developed in the study may help physicians choose the most appropriate management strategy for each patient.

Citing Articles

Predictors of disease recurrence after radical resection and adjuvant chemotherapy in patients with stage IIb-IIIa squamous cell lung cancer: A retrospective analysis.

Senchukova M, Kalinin E, Volchenko N World J Exp Med. 2024; 14(1):89319.

PMID: 38590307 PMC: 10999066. DOI: 10.5493/wjem.v14.i1.89319.

References

Balachandran V, Gonen M, Smith J, DeMatteo R . Nomograms in oncology: more than meets the eye. Lancet Oncol. 2015; 16(4):e173-80. PMC: 4465353. DOI: 10.1016/S1470-2045(14)71116-7. View

Chansky K, Sculier J, Crowley J, Giroux D, Meerbeeck J, Goldstraw P . The International Association for the Study of Lung Cancer Staging Project: prognostic factors and pathologic TNM stage in surgically managed non-small cell lung cancer. J Thorac Oncol. 2009; 4(7):792-801. DOI: 10.1097/JTO.0b013e3181a7716e. View

Dong Y, Sun J, Li Y, Chen Q, Liu Q, Sun Z . Development and Validation of a Nomogram for Assessing Survival in Patients With COVID-19 Pneumonia. Clin Infect Dis. 2020; 72(4):652-660. PMC: 7454485. DOI: 10.1093/cid/ciaa963. View

Morgensztern D, Du L, Waqar S, Patel A, Samson P, Devarakonda S . Adjuvant Chemotherapy for Patients with T2N0M0 NSCLC. J Thorac Oncol. 2016; 11(10):1729-35. PMC: 5141602. DOI: 10.1016/j.jtho.2016.05.022. View

Birim O, Kappetein A, Waleboer M, Puvimanasinghe J, Eijkemans M, Steyerberg E . Long-term survival after non-small cell lung cancer surgery: development and validation of a prognostic model with a preoperative and postoperative mode. J Thorac Cardiovasc Surg. 2006; 132(3):491-8. DOI: 10.1016/j.jtcvs.2006.04.010. View

Canter R, Qin L, Maki R, Brennan M, Ladanyi M, Singer S . A synovial sarcoma-specific preoperative nomogram supports a survival benefit to ifosfamide-based chemotherapy and improves risk stratification for patients. Clin Cancer Res. 2008; 14(24):8191-7. PMC: 2779709. DOI: 10.1158/1078-0432.CCR-08-0843. View

Tu Z, Li C, Tian T, Chen Q . A risk classification system predicting the cancer-specific survival for postoperative stage IB non-small-cell lung cancer patients without lymphovascular and visceral pleural invasion. Lung Cancer. 2021; 161:114-121. DOI: 10.1016/j.lungcan.2021.09.014. View

Sculier J, Chansky K, Crowley J, Meerbeeck J, Goldstraw P . The impact of additional prognostic factors on survival and their relationship with the anatomical extent of disease expressed by the 6th Edition of the TNM Classification of Malignant Tumors and the proposals for the 7th Edition. J Thorac Oncol. 2008; 3(5):457-66. DOI: 10.1097/JTO.0b013e31816de2b8. View

Wang W, Teng F, Bu S, Xu W, Cai Q, Jiang Y . A Population-Based Study on the Prognostic factors and Efficacy of Adjuvant Chemotherapy in the Postoperative Stage for Patients with Stage IIA Non-Small Cell Lung Cancer. Risk Manag Healthc Policy. 2022; 15:1581-1592. PMC: 9423734. DOI: 10.2147/RMHP.S373510. View

10.

Douillard J, Rosell R, De Lena M, Carpagnano F, Ramlau R, Gonzales-Larriba J . Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol. 2006; 7(9):719-27. DOI: 10.1016/S1470-2045(06)70804-X. View

11.

He J, Shen J, Yang C, Jiang L, Liang W, Shi X . Adjuvant Chemotherapy for the Completely Resected Stage IB Nonsmall Cell Lung Cancer: A Systematic Review and Meta-Analysis. Medicine (Baltimore). 2015; 94(22):e903. PMC: 4616365. DOI: 10.1097/MD.0000000000000903. View

12.

Wang Y, Li J, Xia Y, Gong R, Wang K, Yan Z . Prognostic nomogram for intrahepatic cholangiocarcinoma after partial hepatectomy. J Clin Oncol. 2013; 31(9):1188-95. DOI: 10.1200/JCO.2012.41.5984. View

13.

Song X, Xie Y, Deng H, Yu F, Wang S, Lou Y . A Novel Nomogram for Identifying Candidates for Adjuvant Chemotherapy in Patients With Stage IB Non-small Cell Lung Cancer. Cancer Control. 2023; 30:10732748231177541. PMC: 10201645. DOI: 10.1177/10732748231177541. View

14.

Winton T, Livingston R, Johnson D, Rigas J, Johnston M, Butts C . Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med. 2005; 352(25):2589-97. DOI: 10.1056/NEJMoa043623. View

15.

Xu Y, Wan B, Zhu S, Zhang T, Xie J, Liu H . Effect of Adjuvant Chemotherapy on Survival of Patients With 8th Edition Stage IB Non-Small Cell Lung Cancer. Front Oncol. 2022; 11:784289. PMC: 8828472. DOI: 10.3389/fonc.2021.784289. View

16.

Ettinger D, Wood D, Aisner D, Akerley W, Bauman J, Bharat A . NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 2.2021. J Natl Compr Canc Netw. 2021; 19(3):254-266. DOI: 10.6004/jnccn.2021.0013. View

17.

Butts C, Ding K, Seymour L, Twumasi-Ankrah P, Graham B, Gandara D . Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non-small-cell lung cancer: updated survival analysis of JBR-10. J Clin Oncol. 2009; 28(1):29-34. PMC: 2799232. DOI: 10.1200/JCO.2009.24.0333. View

18.

Arriagada R, Auperin A, Burdett S, Higgins J, Johnson D, Le Chevalier T . Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data. Lancet. 2010; 375(9722):1267-77. PMC: 2853682. DOI: 10.1016/S0140-6736(10)60059-1. View

19.

Zeng Y, Mayne N, Yang C, DAmico T, Ng C, Liu C . A Nomogram for Predicting Cancer-Specific Survival of TNM 8th Edition Stage I Non-small-cell Lung Cancer. Ann Surg Oncol. 2019; 26(7):2053-2062. DOI: 10.1245/s10434-019-07318-7. View

20.

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View